Nucleophosmin

Predominantly localized in the CELL NUCLEOLUS, involved in diverse cellular processes such as ribosome biogenesis, cytoplasmic-nuclear trafficking, centrosome duplication, and regulation of p53.

Also Known As:

B23, Nucleolar Phosphoprotein; B23, Nucleolar Protein; B23, Nucleolus Phosphoprotein; B23, Protein; Nucleolus Phosphoprotein B23; Phosphoprotein B23, Nucleolar; Protein B23, Nucleolar; Protein, NO38; NO38 Protein; Nucleolar Phosphoprotein B23; Nucleolar Protein B23; Nucleophosmid; Numatrin; Phosphoprotein B23, Nucleolus; Protein B23

Networked: 722 relevant articles (14 outcomes, 56 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Nuclear Proteins: 2678
    - Nucleophosmin: 722

Experts

1.	Falini, Brunangelo: 36 articles (12/2021 - 03/2002)
2.	Martelli, Maria Paola: 18 articles (12/2021 - 06/2006)
3.	Zhang, Ling: 15 articles (01/2022 - 06/2007)
4.	Mecucci, Cristina: 15 articles (05/2008 - 01/2005)
5.	Marasco, Daniela: 13 articles (10/2022 - 09/2015)
6.	Martelli, Massimo F: 13 articles (11/2010 - 01/2005)
7.	Falini, B: 12 articles (02/2015 - 01/2000)
8.	Döhner, Hartmut: 11 articles (01/2019 - 12/2005)
9.	Liso, Arcangelo: 11 articles (01/2011 - 01/2005)
10.	Bolli, Niccolò: 10 articles (01/2011 - 04/2006)

Related Diseases

1.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 03/01/2007 - "NPM1 gene mutations causing aberrant cytoplasmic localization of nucleophosmin have been demonstrated to be the most frequent submicroscopic alterations in cytogenetically normal acute myeloid leukemia and to confer improved prognosis, especially in patients without a concomitant FLT3 gene internal tandem duplication. " 07/01/2023 - "In this study, the Raman spectral characteristics of nucleophosmin (NPM1)-mutant acute myeloid leukemia (AML) cells and nonmutated AML cells were investigated, and the reasons for the differences in spectral peaks were explained in combination with transcriptomic analysis. " 06/01/2021 - "Our study aims was molecular study of Nucleophosmin -1 gene in Acute Myeloid Leukemia in Kurdish population. " 06/01/2021 - "Molecular study of Nucleophosmin 1(NPM1) gene in acute myeloid leukemia in Kurdish population." 04/01/2020 - "In this study, we aimed at exploring and validating the prognostic value of PLA2G4A expression in patients with non-M3/nucleophosmin (NPM1) wildtype (WT) acute myeloid leukemia (AML) by using two independent datasets. "
2.	Neoplasms (Cancer) 01/01/2023 - "Nucleophosmin 1 (NPM1) has been directly linked to the development of human tumors and may have both tumor-suppressing and oncogenic properties. " 01/01/2023 - "Nucleophosmin Plays a Role in Repairing DNA Damage and Is a Target for Cancer Treatment." 01/13/2022 - "The Role of Nucleophosmin 1 (NPM1) Mutation in the Diagnosis and Management of Myeloid Neoplasms." 01/01/2022 - "Puf-A promotes cancer progression by interacting with nucleophosmin in nucleolus." 11/01/2021 - "The potential role of nucleophosmin (NPM1) in the development of cancer."
3.	Leukemia 03/01/2016 - "We retrospectively analyzed the role of alloHCT in first remission in relationship to the allelic ratio and presence or absence of nucleophosmin 1 mutations (NPM1) in the Study Alliance Leukemia AML2003 trial. " 02/04/2016 - "Sensitive detection of a leukemia-specific marker (e.g., a mutation in the gene encoding nucleophosmin [NPM1]) could improve prognostication by identifying submicroscopic disease during remission. " 07/01/2023 - "Recognition of Nucleophosmin Mutant Gene Expression of Leukemia Cells Using Raman Spectroscopy." 01/01/2023 - "The recent European Leukemia Net (ELN2022) recommendations re-classified AML with FLT3 internal tandem duplications (FLT3-ITD) as intermediate risk regardless of Nucleophosmin 1 (NPM1) co-mutation or the FLT3 allelic ratio. " 01/01/2022 - "Menin inhibitors constitute a novel class of agents targeting the underlying biology of nucleophosmin (NPM1) mutant and KMT2A (formerly known as MLL1) rearranged (KMT2Ar) acute leukemias. "
4.	Residual Neoplasm 06/13/2014 - "In addition, blasts of patients with mutant nucleophosmin (NPM1) revealed significantly higher CD33 and CD123 expression pointing toward the possibility of minimal residual disease-guided interventions in mutated NPM1-positive AMLs. " 06/01/2007 - "Clinical research has revealed that NPM mutations are relative to prognosis and can be used to monitor and quantify minimal residual disease (MRD) in AML patients with normal karyotype, therefore, these findings indicate that nucleophosmin mutations might contribute to illustration of myeloid leukemogenesis. " 10/01/2016 - "Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia." 01/01/2020 - "For acute myeloid leukemia (AML) with nucleophosmin 1 mutation (NPM1m), multiparameter flow cytometry (FCM) and real-time quantitative polymerase chain reaction (RQ-PCR) are used to monitor minimal residual disease (MRD). " 04/01/2009 - "A novel quantitative assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPM1 (nucleophosmin) exon 12 mutations."
5.	T-Cell Lymphoma (Lymphoma, T Cell) 08/15/2003 - "The leader peptide of MMTV Env precursor localizes to the nucleoli in MMTV-derived T cell lymphomas and interacts with nucleolar protein B23." 01/01/2017 - "ALK was first identified in a subset of T-cell lymphomas with anaplastic large cell lymphoma (ALCL) morphology (ALK+ ALCL), the vast majority of which harbor the well-characterized nucleophosmin (NPM)-ALK fusion protein. " 01/01/2022 - "This study reports that hairy and enhancer of split homolog-1 (HES1), known to repress gene transcription in progenitor cells of several cell lineages, was strongly expressed in cells and tissues of T-cell lymphoma expressing the oncogenic chimeric tyrosine kinase nucleophosmin (NPM)-anaplastic lymphoma kinase [ALK; ALK+ T-cell lymphoma (TCL)]. " 04/01/2009 - "Among the many oncogenic variants of the anaplastic lymphoma kinase (ALK), nucleophosmin 1 (NPM)/ALK fusion protein expressed in the subset of T-cell lymphoma (ALK(+)TCL) is currently the best characterized. " 03/17/2011 - "In this study, we report that T-cell lymphoma (TCL) cells carrying the nucleophosmin (NPM)/ALK fusion protein (ALK+ TCL) strongly express hypoxia-induced factor 1α (HIF1α) mRNA, even under normoxic conditions, and markedly upregulate HIF1α protein expression under hypoxia. "

Related Drugs and Biologics

1.	Phosphotransferases (Kinase)
2.	Formaldehyde (Formol)
3.	Nuclear Proteins (Protein, Nuclear)
4.	CCAAT-Enhancer-Binding Protein-alpha
5.	Vincristine (Oncovin)
6.	Prednisone (Sone)
7.	Cyclophosphamide (Cytoxan)
8.	Brentuximab Vedotin
9.	fms-Like Tyrosine Kinase 3
10.	Proteins (Proteins, Gene)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Cell Transplantation
4.	Induction Chemotherapy
5.	Immunotherapy